Is Macrobid (nitrofurantoin) safe to use in the 3rd trimester of pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Macrobid (Nitrofurantoin) Use in the 3rd Trimester

Yes, Macrobid can be used in the 3rd trimester as a first-line agent for urinary tract infections, though it should be avoided at term (near delivery) due to theoretical risk of neonatal hemolytic anemia.

Evidence-Based Recommendation

The American College of Obstetricians and Gynecologists (ACOG) explicitly states that nitrofurantoin may continue to be used as a first-line agent during the second and third trimesters for treatment and prevention of urinary tract infections 1, 2. This represents the highest quality guideline evidence available and should guide clinical practice.

Key Clinical Considerations

Safety Profile Throughout Pregnancy

  • Second and third trimesters: Nitrofurantoin is considered safe and appropriate as first-line therapy for UTIs 1, 2
  • Near term/delivery: Traditional teaching suggests avoiding nitrofurantoin in the final weeks due to theoretical risk of hemolytic anemia in neonates with G6PD deficiency, though this risk is largely theoretical 3
  • First trimester: Can be used when no suitable alternatives exist, though evidence is mixed regarding birth defects 1, 2

Supporting Evidence

  • A retrospective analysis of 91 pregnancies treated with nitrofurantoin macrocrystals showed no significant difference in adverse fetal outcomes compared to the general U.S. population, with no drug-related abnormal events 4
  • Postcoital prophylaxis with nitrofurantoin 50mg during pregnancy was highly effective in preventing recurrent UTIs, with only 1 UTI occurring during pregnancy compared to 130 UTIs in the pre-prophylaxis period 5
  • Multiple studies confirm that nitrofurantoin exposure during pregnancy is not associated with increased risk of fetal malformations 6

Practical Algorithm for Use

When prescribing in the 3rd trimester:

  1. Weeks 14-36: Use nitrofurantoin as first-line therapy without hesitation 1, 2
  2. Week 37 onward (at term): Consider alternative antibiotics (cephalexin, amoxicillin) to avoid theoretical neonatal hemolysis risk 3
  3. If delivery is imminent: Switch to beta-lactam antibiotics if possible 3

Important Caveats

  • Untreated infections pose greater risk: ACOG emphasizes that pregnant women should not be denied appropriate antibiotic treatment, as untreated infections commonly lead to serious maternal and fetal complications 1, 2
  • Use shortest effective duration: As with all antibiotics in pregnancy, prescribe only for appropriate indications and the shortest effective duration 1, 2
  • G6PD deficiency: If known G6PD deficiency in the mother or suspected in the neonate, avoid nitrofurantoin entirely 3

Bottom Line

Nitrofurantoin is safe and effective throughout most of the third trimester, with the only caveat being avoidance in the final weeks approaching delivery due to theoretical neonatal risks. The evidence strongly supports its use as first-line therapy for UTIs in pregnancy, and withholding treatment poses greater maternal-fetal risk than the medication itself 1, 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Effective prophylaxis for recurrent urinary tract infections during pregnancy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1992

Research

Urinary tract infections in pregnancy.

Canadian family physician Medecin de famille canadien, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.